MOTS-c (Mitochondrial Peptide)

MOTS-c Mechanism: AMPK Activation via the Folate Cycle

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

MOTS-c activates AMP-activated protein kinase without raising the AMP-to-ATP ratio. It inhibits the folate cycle and de novo purine biosynthesis, causing the endogenous AMPK activator AICAR to accumulate. AMPK activation follows from that accumulation, making the mechanism metabolite-mediated rather than direct.

Key facts

Target pathway
Folate cycle / de novo purine biosynthesis
Accumulating metabolite
AICAR
Downstream kinase
AMPK
Canonical AMPK trigger
Rising AMP:ATP ratio (not used here)
Reported downstream effect
GLUT4 translocation
Primary reference
Lee et al., Cell Metab 2015 (PMID 25738459)

What AMPK is and why it matters

AMP-activated protein kinase is the cell's principal energy sensor. When energy charge falls, AMPK switches the cell from anabolic to catabolic behaviour, increasing glucose uptake and fatty-acid oxidation, suppressing synthetic pathways. It is normally activated by AMP and ADP binding directly to its gamma subunit, which is why AMPK activation is usually understood as a direct readout of the AMP-to-ATP ratio.

The route MOTS-c takes instead

MOTS-c does not raise the AMP-to-ATP ratio. It interferes with the folate cycle, the one-carbon metabolic pathway that supplies carbon units for de novo purine biosynthesis. Blocking that pathway causes AICAR (an intermediate of purine synthesis and a well-characterised endogenous AMPK activator) to build up. AMPK then responds to AICAR. The peptide never touches AMPK itself.

Research material referenced

MOTS-C 10mg, third-party HPLC tested

Buy MOTS-C · £24.99

Why AICAR is the relevant intermediate

AICAR is structurally an AMP mimetic. Once phosphorylated inside the cell to ZMP, it binds the same regulatory site on AMPK that AMP occupies. This is not a novel mechanism invented for MOTS-c. AICAR has been used as a laboratory AMPK activator for decades. What MOTS-c does is raise it endogenously by constricting the pathway that consumes it.

How this differs from metformin

Metformin is also an indirect AMPK activator, but by a different route: it inhibits mitochondrial complex I, which lowers ATP production and does raise the AMP-to-ATP ratio. MOTS-c arrives at the same kinase through one-carbon metabolism without impairing respiration. Two indirect activators, two entirely different upstream mechanisms.

Reported downstream effects

The 2015 paper reported GLUT4 translocation and effects on glucose handling in mouse models, consistent with AMPK activation. Later work has examined mitochondrial respiration in tissue models. All of this is preclinical, and the effects are reported for the models studied rather than established for humans.

Why the indirectness is scientifically interesting

A mitochondrially encoded peptide that regulates a cytosolic energy sensor through a one-carbon metabolic pathway is a unusual signalling architecture. It connects mitochondrial gene expression to nuclear-genome-encoded metabolism through a diffusible small-molecule intermediate, which is a different kind of communication from a receptor-ligand interaction.

Frequently asked questions

Does MOTS-c bind AMPK directly?

No. It acts upstream, on the folate cycle, and AMPK responds to the resulting AICAR accumulation.

Is this the same mechanism as metformin?

No. Both activate AMPK indirectly, but metformin inhibits complex I and raises the AMP-to-ATP ratio, while MOTS-c works through one-carbon metabolism.

What is AICAR?

5-aminoimidazole-4-carboxamide ribonucleotide, an intermediate of purine synthesis that acts as an AMP mimetic and activates AMPK once phosphorylated to ZMP.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MOTS-c (Mitochondrial Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.